Abstract: The present application relates to fusion proteins, chimeric antigen bearing cells expressing fusion proteins and compositions comprising chimeric antigen bearing cells expressing fusion proteins. The application further relates to methods of using the fusion proteins, cells and compositions for modulating an immune response.
Abstract: Provided are IFN-?-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.
Type:
Grant
Filed:
January 3, 2019
Date of Patent:
February 16, 2021
Assignee:
Eutilex Co., Ltd.
Inventors:
Byoung S Kwon, Seoung-Joo Lee, Joong Won Lee, Seunghyun Lee
Abstract: A novel and thermostable lyophilized pharmaceutical composition of Romiplostim (Fcpeptide fusion protein) along with buffer, bulking agent, stabilizer, and surfactant at pH range of 4.0-6.0.
Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
Type:
Grant
Filed:
January 26, 2018
Date of Patent:
February 9, 2021
Assignee:
Morphosys AG
Inventors:
Stefan Hartle, Stephane Leclair, Amgad Shebl, Stefan Steidl, Bodo Brocks, Daniela Della Ducata, Kai Rosport
Abstract: A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), Mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.
Type:
Grant
Filed:
August 13, 2019
Date of Patent:
February 9, 2021
Assignee:
The Regents of the University of Colorado, a body corporate
Abstract: The present invention relates, in part, to chimeric proteins comprising consensus interferon, or a variant thereof, and their use as therapeutic agents.
Abstract: The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer.
Abstract: The invention provides novel methods of determining or comparing potency of a test interferon relative to rSIFN-co (an interferon having therapeutic effects on solid tumors); methods of establishing substantial equivalence between a test interferon and rSIFN-co; as well as methods for determining potency of a test interferon, kits for determination of such methods, and an interferon or an interferon substitute having said activities.
Abstract: The present invention provides compositions and methods that can be used to determine a peptide signature for an antibody repertoire in a sample comprising multiple antibodies. The method can be used to characterize a phenotype in a sample, such as providing a diagnosis, prognosis or theranosis of a medical condition.
Type:
Grant
Filed:
August 19, 2019
Date of Patent:
December 22, 2020
Assignee:
SERIMMUNE INC.
Inventors:
Patrick Sean Daugherty, Kathryn Vinaya Louise Kamath, Jack Ryan Reifert
Abstract: The present invention relates to vesicles derived from genus Morganella bacteria and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples derived from patients with a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer and lymphoma, a cardiovascular disease such as myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, and stroke, diabetes mellitus, and Parkinson's disease as compared to normal persons, and the vesicles suppressed the secretion of inflammatory mediators by pathogenic vesicles and suppressed the occurrence of cancer, so that the vesicles derived from genus Morganella bacteria may be usefully used for the purpose of developing a method for diagnosing a malignant disease such as gastric cancer, colorectal cancer, pancreatic cancer, bile duct cancer, breast cancer, ovarian cancer, bladder cance
Abstract: The present invention relates to an attenuated Piscirickettsia salmonis bacterium. The bacterium comprises mutations in the amino acid sequence of each of the rpoD, FecR, ATP-grasp domain protein, and FtsH gene products. The invention also relates to vaccines comprising the attenuated Piscirickettsia salmonis bacterium that are useful for the prevention of microbial pathogenesis. In addition, the invention relates to methods for the preparation of attenuated Piscirickettsia salmonis bacteria, and vaccines comprising such bacteria.
Abstract: The invention provides a method for determining a Systemic Lupus Erythematosus-associated disease state in a subject comprising the steps of (a) providing a sample to be tested; and (b) measuring the presence and/or amount in the test sample of one or more biomarker(s) selected from the group defined in Table 1, wherein the presence and/or amount in the test sample of the one or more biomarker(s) selected from the group defined in Table 1 is indicative of a Systemic Lupus. The invention also provides an array and a kit suitable for use in the methods of the invention.
Type:
Grant
Filed:
May 25, 2018
Date of Patent:
December 8, 2020
Assignee:
Immunovia AB
Inventors:
Carl Arne Krister Borrebaeck, Lars Bertil Christer Wingren
Abstract: The present disclosure relates to a method for inhibiting intracellular activated (GTP-bound) RAS using an intact immunoglobulin-type antibody having the ability to penetrate the cytosol, and to the use thereof. The disclosure further relates to a heavy-chain variable region (VH) which induces an intact immunoglobulin-type antibody to penetrate the cytosol and bind to activated RAS in the cytosol, and to an antibody comprising the same. The disclosure correspondingly provides a method for inhibiting the growth of cancer or tumor cells using the antibody, and a method for treating cancer or tumor.
Type:
Grant
Filed:
July 22, 2015
Date of Patent:
December 1, 2020
Assignee:
ORUM THERAPEUTICS INC.
Inventors:
Yong-Sung Kim, Dong-Ki Choi, Seung-Min Shin, Sung-Hoon Kim
Abstract: A method for increase the presentation of ETEC CS6 antigen on a cell surface, comprising the step of contacting cells expressing said antigen with an aqueous solution comprising 0.6-2.2 percent phenol by weight, such that the presentation of said antigen is increased by at least 100%. A method for the manufacture of a killed whole cell vaccine for immunization against CS6-expressing ETEC. Cells and vaccines obtainable by the above methods.
Type:
Grant
Filed:
September 11, 2019
Date of Patent:
December 1, 2020
Assignee:
SCANDINAVIAN BIOPHARMA HOLDING AB
Inventors:
Nils Carlin, Ann-Mari Svennerholm, Joshua Tobias
Abstract: This disclosure relates to an anti-Pseudomonas Psl binding molecule and uses thereof, in particular in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
Type:
Grant
Filed:
May 1, 2019
Date of Patent:
November 24, 2020
Assignee:
MedImmune Limited
Inventors:
Antonio DiGiandomenico, Paul G. Warrener, Charles K. Stover, Bret Sellman, Sandrine Guillard, Ralph Minter, Steven Rust, Mladen Tomich
Abstract: The present invention is directed to a bioconjugate vaccine, such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, D/E-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O1-bioconjugate in a bioreactor comprising a number steps.
Type:
Grant
Filed:
October 23, 2014
Date of Patent:
November 17, 2020
Assignee:
GlaxoSmithKline Biologicals SA
Inventors:
Fabiana Fernandez, Michael Wetter, Michael Kowarik, Michael Wacker
Abstract: A vaccine preparation comprising an antigen for use in the prophylactic or therapeutic treatment of a subject by intradermal administration through laser-generated micropores, wherein the antigen is linked to a binder of a dermal migratory antigen-presenting cell (APC); and a pharmaceutical preparation comprising an active substance for use in the prophylactic or therapeutic treatment of a subject by intradermal administration through laser-generated micropores, for regional delivery to a target location. The invention further relates to the laser-assisted intradermal administration of antigens accompanied by repeated chemotherapy.
Type:
Grant
Filed:
April 20, 2016
Date of Patent:
November 10, 2020
Assignee:
PANTEC BIOSOLUTIONS AG
Inventors:
Reinhard Braun, Dorothea Terhorst, Sandrine Henri, Bernard Malissen, Yoan J. Machado, Mellissa Mayr, Theresa Thalhamer, Veronika Höpflinger, Josef Thalhamer, Richard Weiss
Abstract: In various embodiments chimeric moieties (constructs) are provided that show significant efficacy against cancers. In certain embodiments the constructs comprise a targeting moiety that specifically binds CSPG4 attached to an interferon or to a mutant interferon. In certain embodiments, the constructs comprise anti-CSPG4 antibody attached to an interferon alpha (IFN-?) or to a mutant interferon alpha or to an interferon beta (IFN-?) or to a nutant interferon beta, or to an interferon gamma (IFN-?) or to a mutant interferon gamma.
Type:
Grant
Filed:
October 2, 2018
Date of Patent:
November 3, 2020
Assignee:
The Regents of the University of California
Inventors:
Sherie L. Morrison, John M. Timmerman, Kham M. Trinh
Abstract: Bordetella pertussis iron receptor proteins or portions thereof (e.g., one or more extracellular domains), alone or spliced into B. pertussis scaffold proteins (e.g., fimbrial or flagellin), are provided and can be used in acellular vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals. In addition, Bordetella species grown under iron-starved conditions are provided and can be used in whole cell vaccines to protect against pertussis or other Bordetella diseases in humans and non-human mammals.
Type:
Grant
Filed:
March 30, 2017
Date of Patent:
October 13, 2020
Assignee:
Regents of the University of Minnesota
Inventors:
Timothy Joseph Brickman, Sandra Kay Armstrong
Abstract: A system and method for detecting status of a health condition in a single-step process includes: a signal output device including a) a loading zone; b) a reaction zone fluidly coupled to the loading zone and including one or more reaction substances conjugated to labels, configured to enable detection of target material associated with the health condition; c) a testing zone fluidly coupled to the reaction zone and including one or more testing substances corresponding to the target material; and d) a control zone including a control substance retained at the control zone. The system and methods can be adapted for assessment of sexual health of one or more subjects, in relation to pregnancy, fertility, and/or sexually transmitted infections caused by one or more agents including, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, Treponema pallidum, Gardnerella vaginitis, human immunodeficiency virus, human papillomavirus infection, Hepatitis B, and herpes simplex virus.
Type:
Grant
Filed:
September 13, 2019
Date of Patent:
October 6, 2020
Assignee:
SIMPLE HEALTHKIT, INC.
Inventors:
Sheena Ruby Menezes, Jerzy Majka, Linus Ryan Aranha, Quynh Nga Thi Le